Abstract
Retrometabolic drug design approaches (RMDD) combine quantitative structure-activity and structure-metabolism relations (QSAR and QSMR) to improve the therapeutic index (ratio of toxic and effective dose, TI = TD50/ED50), of newly designed drugs. Soft drug (SD) design approaches, a subclass of RMDD, have been successfully employed in the development of safer drugs. The combination of “soft analog” and “inactive metabolite” techniques in drug development was first exemplified by the highly successful and safe soft corticosteroid, Loteprednol Etabonate. Similar techniques have been used to design safe topically active anticholinergic drugs with much reduced side effects. The “soft analog” and some of the “inactive metabolite” approaches have led to improved antimuscarinic drug candidates, which all (n = 76) can be fit with a bilinear exponential equation of activity vs molecular descriptors. The “remote inactive metabolite” approach was the most successful, having resulted in the new and very safe drug Sofpironium Bromide, which received regulatory approval to treat hyperhidrosis, a debilitating idiopathic disease and an unmet need.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
